Hepatitis C: A review

Plastic and Reconstructive Surgery

Volumn 112, Issue 2, 2003, Pages 597-605

  Yoho, Robert A ^a   Cruz, Leonard L ^a   Mazaheri, Reza ^a   Cruz, Andrea T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; HEPATITIS C VACCINE; RIBAVIRIN; RNA;

EARLY DIAGNOSIS; FLAVIVIRUS; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RNA VIRUS; SCREENING TEST; VIRUS IDENTIFICATION; VIRUS ISOLATION;

HEPATITIS C; HUMANS;

EID: 0041629456     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000070701.04809.95     Document Type: Review

References (66)

1. Krugman, S., Giles, J. P., and Hammond, J. Infectious hepatitis: Evidence for two distinctive clinical, epidemiological, and immunological types of infection. J.A.M.A. 200: 365, 1967.
2. Kuo, G., Choo, Q. L., Alter, H. J., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis genome. Science 244: 362, 1989.
3. Simmonds, P., Alberti, R. H., and Purcell, R. H. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin. Liver Dis. 15: 41, 1995.
4. Alter, H.J., and Seef, L. B. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin. Liver Dis. 20: 17, 2000.
5. Resti, M., Azzari, C., Lega, L., et al. Mother-to-infant transmission of hepatitis C virus. Acta Paediatr. 84:251, 1995.
6. Fanning, L., Kenny, E., Sheehan, M., et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogenous patient population. Hepatology 29: 904, 1999.
7. Zein, N. N., Raklea, J., Krawitt, E. L., Reddy, K. R., Tominaga, T., and Persing, D. H. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Ann. Intern. Med. 125: 634, 1996.
8. Lam, N. P., Neumann, A. U., Gretch, D. R., Wiley, T. E., Perelson, A. S., and Layden, T. J. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon α. Hepatology 26: 226, 1997.
9. Lee, S. S., Heathcote, E. J., Reddy, R., et al. Prognostic factors and early predictability of sustained viral response (SVR) in patients treated with pegylated (40DKA) interferon α-2A (PEGASYS): A new profile (Abstract). Hepatology 32: 370A, 2000.
10. Booth, J. C. L., Foster, G. R., Kumar, U., et al. Chronic hepatitis C virus infection: Predictive value of genotype and level of viremia on disease progression and response to interferon α. Gut 36: 427, 1995.
11. Manns, M. P., McHutchinson, J. G., Gordon, S. C., et al. Peginterferon α-2b in combination with ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: Results of a randomized trial. Lancet 358: 958, 2001.
12. Thomas, D. L., Astemborski, J., Rai, R. M., et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. J.A.M.A. 284: 450, 2000.
13. Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., and Thomas, D. L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29: 908, 1999.
14. Neiderau, C., Lange, S., Heintges, T., et al. Prognosis of chronic hepatitis C: Results of a large prospective cohort study. Hepatology 28: 1687, 1998.
15. Jaeckel, E., Cornberg, M., Wedemyer, H., et al. Treatment of acute hepatitis C with interferon α-2b. N. Engl. J. Med. 345: 1452, 2001.
16. Roudot-Thoroval, F., Basite, A., Pawletsky, J. M., Dhumeauz, D., and the Study Group for the Prevalence and Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6664 patients. Hepatology 26: 485, 1997.
17. Ymauchi, M., Nakahua, M., Maezawa, Y., Satoh, S., Nishikawa, F., and Ohata, M. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am. J. Gastroenterol. 88: 39, 1993.
18. Schrieber, G. B., Busch, M. P., Kleinman, S. H., and Korelitz, J.J. The risk of transfusion-transmitted viral infections: The Retrovirus Epidemiology Donor Study. N. Engl. J. Med. 334: 1685, 1996.
19. Belanger, K. J., Kelly, D. J., Metille, F. C., Hanson, C. V., and Lippert, L. E. Psoralen photochemical inactivation of Orientia tsutsugamushi in platelet concentrates. Transfusion 40: 1503, 2000.
20. Abe, H., Yamada-Ohnishi, Y., Hirayama, J., Owada, T., Ikeda, H., and Ikebuchi, K. Elimination of both cell-free and cell-associated HIV infectivity in plasma by a filtration/methylene blue photoinactivation system. Transfusion 40: 1081, 2000.
21. Lustigman, S., and Ben-Hur, E. Photosensitized inactivation of Plasmodium falciparum in human red cells by phthalocyanines. Transfusion 36: 543, 1996.
22. McBurney, L. L., Goodrich, T. B., Hansen, E. T., et al. The use of riboflavin for the viral inactivation of platelets (Abstract). Transfusion 40 (Suppl.): 37S, 2000.
23. Stevens, A. B., and Coyle, P. V. Hepatitis C virus: An important occupational hazard? Occup. Med. (Lond.) 50: 377, 2000.
24. Puro, V., Petrasillo, N., and Ippolito, G. Risk of hepatitis seroconversion after occupational exposure in healthcare workers. Am. J. Infect Control 23: 273, 1995.
25. Hepatitis Surveillance Report 56. Atlanta, Ga.: Centers for Disease Control and Prevention, 1995. Pp. 3-6.
26. Esteben, J. I., Gomez, J., Martell, M., et al. Transmission of hepatitis C virus by a cardiac surgeon. N. Engl. J. Med. 334: 555, 1996.
27. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341: 556, 1999.
28. Conte, D., Fraquelli, M., Prati, D., Colucci, A., and Mihola, E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 31: 751, 2000.
29. National Institutes of Health. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 26 (Suppl. 1): 2S, 1997.
30. Alter, M. Epidemiology and disease burden of hepatitis B and C. Antiviral Ther. 1: 9, 1996.
31. Wong, J. B., McQuillan, G. M., McHutchison, J. G., and Poynard, T. Projecting future hepatitis C morbidity and mortality in the US: An awakening giant. Presented at the 50th Annual Meeting of the American Association for the Study of Liver Diseases, Dallas, Texas, November 5-9, 1999.
32. Fattovich, G., Giustina, G., Degos, F., et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 112: 463, 1997.
33. Atler, H. J., Jett, B. W., Polito, A.J., et al. Analysis of the role of hepatitis C virus in transfusion associated hepatitis. In F. B. Hollinger, S. M. Lemon, and H. D. Margolis (Eds.), Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 1991. Pp. 396-402.
34. Chemello, L., Cavaletto, D., Portisso, P., et al. Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. Hepatology. 17: 179, 1993.
35. Lok, A. S. F., Chien, D., Choo, Q. L., et al. Antibody response to core and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients. Hepatology 18: 497, 1993.
36. Davis, G. L., and Lau, J. Y. N. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26 (Suppl. 1): 1050, 1997.
37. Singer, M., and Younossi, Z. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am. J. Med. 111: 614, 2001.
38. Moyer, L. A., Mast, E. E., and Alter, M. J. Hepatitis C: Routine serologic testing and diagnosis. Am. Fam. Physician 59: 79, 1999.
39. Kim, W. R., and Potterucha, J. J. Is it time for mass screening for hepatitis C? Am. J. Med. 111: 667, 2001.
40. Centers for Disease Control and Prevention, Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. M.M.W.R. 47:1, 1998.
41. Yano, M., Kumada, M., Kage, M., et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 23: 1334, 1996.
42. Tsubota, A., Chayoma, K., Ikeda, K., et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 19: 1088, 1994.
43. Haber, M. M., West, A., Hobert, D., and Reuben, A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am. J. Gastroenterol. 90: 1250, 1995.
44. Wilson, R. A. Extrahepatic manifestations of chronic viral hepatitis. Am. J. Gastroenterol. 92: 2, 1997.
45. Levey, J. M., Bjornsson, B., Banner, B., et al. Mixed cryoglobulinemia in chronic hepatitis C infection: A clinico-pathologic analysis of 10 cases and review of recent literature. Medicine 73: 53, 1994.
46. Beaird, J. M., Kahloon, N., Franco, J., and Fairley, J. A. Incidence of hepatitis C in lichen planus. J. Am. Acad. Dermatol. 44: 311, 2001.
47. Sanchez-Perez, J., De Castro, M., Buezo, G. F., Fernandez-Herrera, J., Borque, M. J., and Garcia-Diez, A. Lichen planus and hepatitis C virus: Prevalence and clinical presentation of patients with lichen planus and hepatitis C virus infection. Br. J. Dermatol. 134: 715, 1996.
48. Dron, M., and Tovey, M. G. Interferon α/β gene structure and regulation. In S. Baron, D. H. Coppenhaver, F. Dianzani, et al. (Eds.), Interferons: Principles and Medical Applications. Galveston, Texas: The University of Texas Galveston Branch, 1992. Pp. 23-45.
49. Carithers, R. I., Jr., and Emerson, S. S. Therapy of hepatitis C: Meta-analysis of interferon α-2b trials. Hepatology 26 (Suppl. 1): 835, 1997.
50. Lee, W.M. Therapy of hepatitis C: Interferon α-2a trials. Hepatology 26 (Suppl. 1): 895, 1997.
51. Farrell, G. C. Therapy of hepatitis C: Interferon α-1 trials. Hepatology 26 (Suppl. 1): 965, 1997.
52. Keefe, E. B., Hollinger, F. B., and the Consensus Interferon Study Group. Therapy of hepatitis C consensus interferon trials. Hepatology 26 (Suppl. 1): 1015, 1997.
53. Fried, M. W., Shiffman, M. I., Reddy, R. K., et al. Pegylated (40kDa) interferon α-2a (Pegasys) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study (Abstract). Gastroenterology 120 (Suppl.): A-55, 2001.
54. Lindsay, K. L., Trepo, C., Heintges, T., et al. A randomized, double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 34: 395, 2001.
55. Zuezem, S., Feinman, S. V., Rosenack, J., et al. Peginterferon α-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343: 1666, 2000.
56. Sofair, A. N. Hepatitis C: Latest guidelines from the NIH. Consultant 42: 1722, 2002.
57. Sobesky, R., Mathurin, P., Charlotte, F., et al. Modeling the impact of interferon a treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology 116: 378, 1999.
58. Bizollon, T., Guichard, S., Ahmed, S. N., et al. Impact of hepatitis G virus co-infection on the course of hepatitis C virus infection before and after liver transplantation. J. Hepatol. 29: 893, 1998.
59. Wong, J. B., McQuillan, G. M., McHutchinson, J. G., and Pynard, T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health 90: 1562, 2000.
60. Ray, R. B., Lagging, L. M., Meyer, K., and Ray, R. Hepatitis C virus core protein cooperates with Ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 70: 4438, 1996.
61. Silini, E., Bottelli, R., Asti, M., et al. Hepatitis C virus genotype and risk of hepatocellular carcinoma in cirrhosis: A case-control study. Gastroenterology 111: 199, 1996.
62. Benvegnu, L., Pontissu, P., Cavalletto, D., Noventa, F., Chemello, L., and Alberti, A. Lack of correlation between hepatitis C virus genotypes and clinical course in hepatitis C virus-related cirrhosis. Hepatology 25: 211, 1997.
63. Kassianides, C., and Kew, M. C. The clinical manifestations and natural history of hepatocellular carcinoma. Gastroenterol. Clin. North Am. 16: 553, 1987.
64. DiBesceglie, A. M. Hepatitis C and hepatocellular carcinoma. Hepatology 26: 345, 1997.
65. Choo, Q. L., Kuo, G., Ralston, R., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 91: 1294, 1994.
66. Nemchinov, L. G., Liang, T. J., Rifaat, M. M., Mayzad, H. M., Hadidi, A., and Keith, J. M. Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch. Virol. 145: 2557, 2000.